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Gastrointestinal endoscopyAbstract Objective: To compare the sedative, hemodynamic, respiratory and adverse effects of
dexmedetomidine versus propofol during gastrointestinal endoscopy (GIE) in pediatrics.
Methods: After obtaining approval of the research and ethics committee and informed consent of
the parents of the patients, eighty pediatric patients ASA I/II aged 1–14 years, scheduled for gastro-
intestinal endoscopy were randomized into dexmedetomidine group or propofol group. Sedation
was achieved with propofol 2 mg/kg bolus then infused at 100 lg/kg/min or dexmedetomidine
2.5 lg/kg over 10 min then infused at 2 lg/kg/h to achieve a Ramsay sedation scale (RSS) P5.
HR, MAP, RR and SPO2 were continuously monitored and analyzed at (T0) baseline, (T1) after
induction, (T2) after insertion of endoscope, (T3) during procedure, (T4) recovery period. Times
of induction, procedure, and recovery were reported together with any adverse effects.
Results: There were no signiﬁcant differences in demographic data between the two groups. HR
values were signiﬁcantly lower in dexmedetomidine group at T1, T2 and T3 (83.95 ± 13.79 versus
92.95 ± 12.38, 103.35 ± 15.34 versus 112.75 ± 12.79 and 90.80 ± 13.99 versus 104.05 ± 10.73)
beats/min respectively, (p-value < 0.05). No signiﬁcant differences were found in MAP, RR and
SPO2 values between groups at all time points. Induction and recovery times were signiﬁcantly
longer in dexmedetomidine group 10.51 ± 1.75 versus 3.17 ± 0.72 min and 28.55 ± 7.95 versus
13.68 ± 3.35 min (p-value < 0.001). Seven patients in dexmedetomidine group (17.5%) versus
Table 1 Ramsay sedation score (R
Anxious and agitated
Cooperative, tranquil, oriented
Responds only to verbal commands
Asleep with brisk response to light sti
Asleep without response to light stimu
Non responsive
Table 2 Steward recovery
Consciousness
Awake
Responding to stimuli
Not responding
Airway
Coughing on command or cry
Maintaining good airway
Airway requires maintenance
Movement
Moving limbs purposefully
Non purposeful movements
Not moving
22 A.S. Hasanin, A.M. Siraone patient in propofol group (2.5%) showed unwanted movement (p-value 0.057), and no cases in
dexmedetomidine group demonstrated oxygen desaturation versus 6 patients (15%) within propofol
group (p-value 0.026).
Conclusion: Dexmedetomidine sedation during GIE provides more respiratory safety and HR sta-
bility presenting itself as a suitable alternative agent especially for the relatively longer procedures.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Gastrointestinal endoscopy (GIE) procedures are performed
for diagnosis and management in pediatric gastroenterology
[1], and it allows visual examination with the ability to obtain
biopsy and culture specimens [2]. Pediatric patients have differ-
ent physiological effects in response to pain and anxiety [3]. So
they need proper analgesia and amnesia to allow optimum
procedure circumstances especially for those patients who need
repeated procedures [2–4].
Propofol is used commonly in sedation for pediatric GIE
procedures as it is a powerful sedative characterized by a rapid
onset, short duration of action and rapid recovery [5,6]. Also it
causes mild analgesia and minor adverse effects including;
transient hypotension, dose dependent respiratory depression
and hypoventilation [5].
Dexmedetomidine was approved by the food and drug
administration in the United States in 1999 for use in adult
sedation. Recently it has been introduced in pediatrics in inten-
sive care units and for procedural sedation outside the operat-
ing room. Dexmedetomidine is a highly selective alpha-2 (a2)
adrenergic agonist with a relatively high ratio of a2/a1 activity
when compared with clonidine [7–10]. It possesses sedative,
analgesic, sympatholytic, and hemodynamic stability proper-
ties [8,9]. It has the unique feature of lacking respiratory
depression even with accidental over dosage giving it the
advantage over other sedatives as benzodiazepines, opioidsSS) [11].
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0and propofol as all of them cause dose dependent respiratory
depression [10].
The use of dexmedetomidine for procedural sedation in
pediatric patients was reported in various circumstances
[7,10], however to our knowledge no studies have reported
its use in pediatric GIE.
So in this study we aimed to compare the sedative, hemody-
namic, respiratory, and adverse effects of using dexmedetomi-
dine versus propofol during GIE in pediatric population.
2. Patients and methods
This prospective study was conducted on pediatric patients
scheduled for GIE. After obtaining approval of the research
and ethics committee and informed consent of the parents of
the patients, 80 pediatric patients American society of Anes-
thesiologists classiﬁcations I & II (ASA I/II) aged 1–14 years
were included in the study.
Emergency patients and patients with ASA physical status
more than II were excluded together with any patient who had
bradycardia, or vomiting. Patients on beta blocker manage-
ment or allergic to any component of the study drugs were also
excluded. All GIE procedures were performed with the stan-
dard technique while the patients were in the prone position
with the head tilted to the right side.
No premedications were given to the patients. Patients were
randomized into 2 groups: propofol group (PG) and dexmede-
tomidine group (DG). In the propofol group sedation was in-
duced with propofol (B. Braun Melsungen AG 34209
Melsungen, Germany) bolus 2 mg/kg to achieve a Ramsay
sedation scale (RSS) P5 then propofol infusion started at
100 lg/kg/min for maintenance of sedation. 0.5 mg/kg of pro-
pofol was given as a bolus if there was any sudden movement
or agitation during the procedure.
In the dexmedetomidine group, sedation was induced by
dexmedetomidine (Percedex; Hospira, Inc., Lake Forest, IL
60045 USA), high dose of 2.5 lg/kg was infused over 10 min
to achieve a RSSP 5, and this was followed with continuous
dexmedetomidine infusion at 2 lg/kg/h for maintenance of
sedation. 0.4 lg/kg of dexmedetomidine was given as a bolus
if there was any sudden movement or agitation during the
procedure.
All patients were breathing spontaneously and received
3 L/min oxygen supplementation by nasal catheter during
the procedure while monitored with pulse oximetry, and non-
invasive blood pressure (NIBP).
The sedation protocol was planned to maintain the Ramsay
sedation score equalP5 in addition to the absence of agitation
and signs of insufﬁcient analgesia during introduction of endo-
scope and during the procedure (see Tables 1 and 2).
We recorded induction time (which was deﬁned as the time
from the start of drug intake till achievement of RSSP 5),
procedure time, and recovery time (which was deﬁned as the
Figure 1 Changes in the heart rate (HR) in the two groups, data
are presented as mean ± SD. Dexmedetomidine group (n= 40)
and propofol group (n= 40). T0: before induction of sedation,
T1: after induction of sedation and before insertion of endoscope,
T2: immediately after insertion of endoscope, T3: during proce-
dure, T4: during recovery till steward recovery score becomes 6.
*denotes signiﬁcance between both groups, p-value <0.005,
denotes signiﬁcance within dexmedetomidine group, p-value
<0.001, and denotes signiﬁcance within propofol group p-value
<0.001.
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steward recovery score of 6). Heart rate (HR), mean arterial
blood pressure (MAP), respiratory rate (RR), and oxygen sat-
uration (SPO2) were continuously monitored and analyzed in
the following ﬁve time intervals; before induction of sedation
(T0), after induction of sedation and before insertion of endo-
scope (T1), immediately after insertion of endoscope (T2),
throughout endoscopy procedures starting 5 min after inser-
tion of endoscope (T3), and recovery period till the patient
achieved 6 points on Steward recovery score (T4). The inci-
dence of any unwanted movement that necessitates an incre-
mental bolus of sedative drugs was reported.
We reported any adverse effects as oxygen desaturation
(SPO2 < 90%), need for jaw thrust maneuver or manual ven-
tilation, laryngospasm, any episodes of hypotension (decrease
in MAP> 20%), bradycardia (decrease in HR> 20% of ini-
tial rate or HR< 55/min), vomiting, or shivering.
2.1. Statistical methods
Continuous variables were presented as mean ± SD, while
categorical variables were presented as number and/or percent-
age of total. Independent samples t-test was used to test the
differences between the two groups regarding; age, weight,
times, HR, MAP, RR, and SPO2. Whereas changes in data
within the same group (HR, MAP, RR, & SPO2) were ana-
lyzed using repeated measures analysis of variance, data about
gender, type of GIE, and incidence of side effects were ana-
lyzed with chi-square test or Fisher’s exact test as appropriate.
A p-value <0.05 was considered statistically signiﬁcant and all
analyses were done using SPSS software version 20.
3. Results
No statistically signiﬁcant differences were found between the
two groups regarding age, weight, gender and type of endos-
copy (Table 3).
The heart rate values changed signiﬁcantly over the study
period. In the dexmedetomidine group the heart rate decreased
after induction of sedation (T1) then increased after insertion of
endoscope (T2) when compared with the baseline value (T0)
(for all p-value <0.001). Also in the propofol group after base-
line value (T0) there was initial decrease in HR after induction
of sedation (T1) then HR increased after insertion of endoscope
(T2) and during recovery (T3) (for all p-value <0.001). These
changes were less vigorous in the dexmedetomidine group as
demonstrated by the fact that the heart rate values in the dex-
medetomidine group were maintained signiﬁcantly lower than
in the propofol group at T1, T2 and T3 (83.95 ± 13.79 versus
92.95 ± 12.38, 103.35 ± 15.34 versus 112.75 ± 12.79 and
90.80 ± 13.99 versus 104.05 ± 10.73) beats/min respectively,
for all p-value was <0.05 (Fig. 1).Table 3 Age, weight, gender, and type of endoscopy.
Parameters Dexmedetomidine
Age (year) mean ± SD 8.35 ± 3.82
Weight (kg) mean ± SD 25.54 ± 9.65
Gender (M/F) 22/18
Type of endoscopy (upper/lower) 26/14No statistically signiﬁcant differences were found in MAP
values between the two groups at all time points (Fig. 2). While
analysis of MAP within each group showed signiﬁcant increase
at T2 when compared to T0, this occurred in both groups (p-
value <0.001). The changes in hemodynamics (HR and MAP)
were not clinically important (within 20% of baseline values)
and no interference needed.
The measurements of RR (Fig. 3) and SPO2 (Fig. 4) were
comparable between the two groups all over the study period.
No cases in dexmedetomidine group and six cases (15%) with-
in propofol group demonstrated oxygen desaturation
SPO2 < 90% (p-value = 0.026), which was corrected with
chin lift and increasing the oxygen ﬂow to 6 L/min, but no
cases needed artiﬁcial airway or manual ventilation. Of these
six cases ﬁve were undergoing upper GIE and one case was
undergoing colonoscopy.
The time needed to achieve sedation was signiﬁcantly long-
er in dexmedetomidine group than in propofol group
(10.51 ± 1.75 versus 3.17 ± 0.72 min) p-value <0.001. Also
the recovery time was signiﬁcantly longer in dexmedetomidine
group (28.55 ± 7.95 versus 13.68 ± 3.35 min) p-value <0.001.
The procedure time was comparable in the two groups
(Table 4).
Seven patients (17.5%) in dexmedetomidine group showed
unwanted movement during the procedure which required(n= 40) Propofol (n= 40) P-value
9.94 ± 4.82 0.114
28.11 ± 12.96 0.336
24/16 0.651
25/15 0.816
Figure 2 Changes in mean arterial blood pressure (MAP)
between the two groups and within each group. Data presented
as Mean ± SD. T0: before induction of sedation, T1: after
induction of sedation and before insertion of endoscope, T2:
immediately after insertion of endoscope, T3: during procedure,
T4: during recovery till steward recovery score becomes 6. 
denotes signiﬁcance within dexmedetomidine group, p-value
<0.001 and denotes signiﬁcance within propofol group, p-value
<0.001.
Figure 3 Respiratory rate (RR) changes in the two groups. T0:
before induction of sedation, T1: after induction of sedation and
before insertion of endoscope, T2: immediately after insertion of
endoscope, T3: during procedure, T4: during recovery till steward
recovery score becomes 6.
Figure 4 Changes in oxygen saturation (SPO2) in the two
groups over the study period. T0: before induction of sedation, T1:
after induction of sedation and before insertion of endoscope, T2:
immediately after insertion of endoscope, T3: during procedure,
T4: during recovery till steward recovery score becomes 6.
Table 4 Times of induction of sedation, procedure and
recovery.
Parameters Dexmedetomidin (n= 40) Propofol (n= 40)
Induction time (min) 10.52 ± 1.75 3.17 ± 0.72*
Procedure time (min) 20.70 ± 10.71 19.65 ± 7.69
Recovery time (min) 28.55 ± 7.85 13.68 ± 3.35*
* Denotes signiﬁcant difference between the two groups, p-value
<0.001.
Table 5 Incidence of adverse effects in the two groups.
Parameters Dexmedetomidine
(n= 40)
Propofol (n= 40)
Oxygen desaturation 0 6 (15)*
Unwanted movement 7 (17.5) 1 (2.5)
Vomiting 0 1 (2.5)
Shivering 0 0
Agitation 0 0
Laryngospasm 0 0
Bradycardia 0 0
Hypotension 0 0
Others 0 0
Data are presented as number of patients (%).
* Denotes signiﬁcant difference between the two groups, p-value
0.026 (by Fishers’ exact test).
24 A.S. Hasanin, A.M. Siraincremental bolus of dexmedetomidine versus only one patient
(2.5%) in the propofol group (Table 5).
4. Discussion
In our study, we compared dexmedetomidine versus propofol
as a sedative for GIE procedure in pediatric patients.
There were no signiﬁcant differences between both groups
concerning MAP, while HR changes were more limited in dex-
medetomidine group and HR values were signiﬁcantly lower
than in the propofol group reﬂecting more hemodynamic
stability.
The incidence of oxygen desaturation was more evident
with propofol that gives dexmedetomidine an importantadvantage regarding the respiratory safety and airway
protection.
In pediatrics, there were many doses used in many previous
studies ranging from 1 to 3 lg/kg/10 min for induction of seda-
tion and 0.5–2 lg/kg/h for maintenance. In our study we used
a high dose of dexmedetomidine 2.5 lg/kg/10 min for induc-
tion of sedation and 2 lg/kg/h for maintenance as we used it
as a sole agent. The incidence of unwanted movements that
needed incremental bolus was more in dexmedetomidine
group. Both times of induction and recovery were prolonged
with dexmedetomidine than propofol.
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tion of dexmedetomidine. It acts on the vasomotor center inme-
dulla and on locus ceruleus leading to decreased sympathetic
outﬂow and increased parasympathetic outﬂow, allows for in-
creased action of inhibitory GABA neurons, this together with
triggering neurotransmitters that decrease histamine release
leads to analgesia, sedation and natural rapid eye movement
(REM) sleep without ventilatory depression [9,10] that explains
the low incidence of oxygen desaturation.On the heart sympath-
olysis decreases tachycardia and produces bradycardia by the
vagomimetic action. On the blood vessels central sympatholysis
causes vasodilatation that may lead to hypotension, peripheral
direct action causes vasoconstriction which may cause initial
transient hypertension. Differences inHR andMAPproﬁles be-
tween studies may be rendered to the use of different dose regi-
mens in addition to differences in nature of procedures [10].
The longer induction time with dexmedetomidine was due
to the slow initial infusion over 10 min to avoid the undesirable
hemodynamic changes that occur with faster infusion. Dex-
medetomidine has a short half life (2–3 h) as it is rapidly dis-
tributed and extensively metabolized by the liver, still the
recovery time was longer than that of propofol as propofol
has three times shorter half life (30–60 min) [10].
A previous study [13] compared the effects of dexmedetom-
idine/ketamine and propofol/ketamine combinations in pediat-
ric patients undergoing cardiac catheterization. It showed
similar results as the systolic arterial blood pressure, SPO2,
and RR were comparable between the 2 groups while HR
was lower at 15, 30, and 45 min in dexmedetomidine group.
The sedation scores were comparable between the 2 groups
while BIS values and ketamine consumption were more in dex-
medetomidine group than propofol group. Also, the recovery
time was more prolonged in dexmedetomidine group than pro-
pofol group and oxygen desaturation was observed at a higher
rate with propofol than dexmedetomidine [13].
Another study [14] evaluated the effects of dexmedetomi-
dine as a sedative in pediatric dental patients versus propofol/
midazolam combination. They found that HR, SPO2, & RR
were comparable among both groups during all recorded times,
while MAP was signiﬁcantly lower in propofol group than dex-
medetomidine group at 5, 10, 15 min. The time of induction of
sedation was longer with dexmedetomidine than propofol, but
the recovery time was shorter with dexmedetomidine than pro-
pofol. They explained that by the addition of midazolam to
propofol as previous reports demonstrated that midazolam
use in pediatrics resulted in long duration of action [14].
Koroglu et al. [15] compared dexmedetomidine versus pro-
pofol in children undergoing MRI examination, they found
that dexmedetomidine preserved HR & MAP better than pro-
pofol. Also the incidence of oxygen desaturation was more
with propofol, but the onset of sedation, recovery and dis-
charge time were signiﬁcantly shorter with propofol [15].
Another study by the same authors [16] Koroglu et al.,
compared dexmedetomidine versus midazolam in pediatrics
undergoing MRI using a lower dose of dexmedetomidine, they
found that the rate of adequate sedation was higher with dex-
medetomidine associated with lower requirements of adjunct
drugs. HR, MAP and RR were comparable between both
groups but the onset of sedation was shorter with midazolam.
Ulgey et al., in their study [17] to test the results of addition
of dexmedetomidine to ketamine/propofol combination during
pediatric cardiac catheterization found a signiﬁcant decrease inHR after induction of sedation and throughout the procedure
in addition to a decrease in the incidence of oxygen desatura-
tion. Also, addition of dexmedetomidine to ketamine/propofol
resulted in shorter recovery time explained by the decreased
amount of propofol used [17].
Mason et al., in their study [18] found that IV dexmedetom-
idine sedation was associated with modest ﬂuctuations in HR
and arterial blood pressure independent for age, required no
pharmacologic interventions and didn’t result in any adverse
event and that fall within similar ranges to those published
when propofol and inhalational anesthetics are used to achieve
anesthesia at a target controlled infusion of propofol of
6 lg/ml or up to 1MAC with sevoﬂurane.
In summary, dexmedetomidine sedation in pediatric pa-
tients undergoing GIE procedures had both favorable and
unfavorable aspects as; dexmedetomidine was associated with
more HR stability. Also, the respiratory safety of dexmede-
tomidine as compared to propofol which was associated with
higher incidence of oxygen desaturation, this is an important
advantage of dexmedetomidine sedation especially in upper
GIE procedures which is associated with increased possibilities
of oxygen desaturation.
On the other hand, dexmedetomidine was associated with
signiﬁcant increase in the induction time of sedation and the
recovery time that could affect the rate of turnover of cases
which is an important factor in GIE units. Thus dexmedetom-
idine may be more suitable for the relatively longer procedures
i.e. colonoscopy rather than shorter ones as most of the diag-
nostic and follow up upper GIE.
Also, in spite of using a higher dexmedetomidine dose than
many studies, still some patients needed incremental boluses
suggesting that we may need to increase the maintenance dose
or add an adjunct drug.
In conclusion, dexmedetomidine sedation during GIE pro-
vides more respiratory safety & HR stability presenting itself
as a suitable alternative agent especially for the relatively long-
er procedures.
Conﬂict of interest
None.
References
[1] van Beek EJ, Leroy PL. Safe and effective procedural sedation
for gastrointestinal endoscopy in children. J Pediatr
Gastroenterol Nutr 2012;54:171–85.
[2] Balsells F, Wyllie R, Kay M, Steffen R. Use of conscious
sedation for lower and upper gastrointestinal endoscopic
examinations in children, adolescents, and young adults: a
twelve-year review. Gastrointest Endosc 1997;45:375–80.
[3] Ko BJ, Jang JH, Park JW, Lee SC, Choi SR. Procedural
sedation with dexmedetomidine for pediatric endoscopic
retrograde cholangiopancreatography guided stone retraction.
Korean J Anesthesiol 2012;63:567–8.
[4] Correia LM, Bonilha DQ, Gomes GF, Brito JR, Nakao FS,
Lenz L, et al. Sedation during upper GI endoscopy in cirrhotic
outpatients: a randomized, controlled trial comparing propofol
and fentanyl with midazolam and fentanyl. Gastrointest Endosc
2011;73:45–51.
[5] Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol
for procedural sedation in children in the emergency
department. Ann Emerg Med 2003;42:773–82.
26 A.S. Hasanin, A.M. Sira[6] Lightdale JR, Valim C, Newburg AR, Mahoney LB,
Zgleszewski S, Fox VL. Efﬁciency of propofol versus
midazolam and fentanyl sedation at a pediatric teaching
hospital: a prospective study. Gastrointest Endosc
2008;67:1067–75.
[7] Shukry M, Miller JA. Update on dexmedetomidine: use in
nonintubated patients requiring sedation for surgical
procedures. Ther Clin Risk Manag 2010;15:111–21.
[8] Sudheesh K, Harsoor S. Dexmedetomidine in anaesthesia
practice: a wonder drug? Indian J Anaesth 2011;55:323–4.
[9] AGrewal. Dexmedetomidine: new avenues. J Anaesthesiol Clin
Pharmacol 2011;27:297–302.
[10] McMorrow SP, Abramo TJ. Dexmedetomidine sedation, uses in
pediatric procedural sedation outside the operating room.
Pediatr Emer Care 2012;28:292–6.
[11] Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled
sedation with alphaxalone–alphadolone. Br Med J
1974;22:656–9.
[12] Steward DJ. A simpliﬁed scoring system for the post-operative
recovery room. Can Anaesth Soc J 1975;22:111–3.
[13] Tosun Z, Akin A, Guler G, Esmaoglu A, Boyaci A.
Dexmedetomidine–ketamine and propofol–ketamine
combinations for anesthesia in spontaneously breathing
pediatric patients undergoing cardiac catheterization. J
Cardiothorac Vasc Anesth 2006;20:515–9.[14] Al-Taher WM, Mansour EE, El-Shafei MN. Comparative study
between novel sedative drug (dexmedetomidine) versus
midazolam–propofol for conscious sedation in pediatric
patients undergoing oro-dental procedures. Egypt J Anaesth
2010;26:299–304.
[15] Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM.
A comparison of the sedative, hemodynamic, and respiratory
effects of dexmedetomidine and propofol in children undergoing
magnetic resonance imaging. Anesth Analg 2006;103:63–7.
[16] Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy
MO. Sedative, haemodynamic and respiratory effects of
dexmedetomidine in children undergoing magnetic resonance
imaging examination: preliminary results. Br J Anaesth
2005;94:821–4.
[17] U¨lgey A, Aksu R, Bicer C, Akin A, Altuntas R, Esmaog˘lu A,
et al. Is the addition of dexmedetomidine to a ketamine–
propofol combination in pediatric cardiac catheterization
sedation useful? Pediatr Cardiol 2012;33:770–4.
[18] Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ,
Zurakowski D. Hemodynamic effects of dexmedetomidine
sedation for CT imaging studies. Pediatr Anaesth
2008;18:393–402.
